Protecting against vaccinepreventable. this together
|
|
- Loren Hodges
- 5 years ago
- Views:
Transcription
1 Protecting against vaccinepreventable diseases We are in this together Canadian Immunization Conference December 4, 2014 Litjen (L.J) Tan, MS, PhD Chief Strategy Officer, Immunization Action Coalition Co-Chair, United States Adult and Influenza Immunization Summit
2 Disclosures In the past year, I have received honoraria from Pfizer, Merck, Novartis, Temptime Corp., and TruMedSystems for service as a scientific consultant. My honoraria is donated to the IAC I do NOT intend to discuss an unapproved or investigative use of a commercial product/device in my presentation.
3 Disclaimer The opinions expressed in this presentation are solely those of the presenter and do not necessarily represent the official positions of the Immunization Action Coalition, or the National Adult and Influenza Immunization Summit
4 Outline: We are in this together Immunization successes are generally associated with strong private/public collaboration we are in it together. Adult Immunization are we in it together? Maintaining the future of immunization challenges that keep us apart and how do we get together?
5 Why do we vaccinate? Vaccination is a critical tool for maintaining the public s health A well-vaccinated population will be more resilient to potential public health emergencies (natural disasters resulting in displaced populations, disease outbreaks, etc). Any health infrastructure that is developed and sustained to deliver vaccinations to every child, adolescent, and adult can be leveraged to deliver care, vaccines and medications in times of crisis.
6 Why do we vaccinate? Vaccine, Good! Disease, Bad! Diseases eliminated from the US: Disease Smallpox 1949 Polio 1979 Measles 1993 Rubella 2004 Last Case* *Indigenous case. Importations may occur except for smallpox, which was eradicated from the planet in 1977.
7 Benefits of Immunization are Clear Arguably one of the top public health interventions of all time Tremendous reduction in mortality and morbidity attributed to immunization Vaccine-preventable disease rates in children in the US have been dramatically reduced; some are close to eradication Vaccines save money as well as lives Increasing interest in disease prevention in US Immunizations are an important preventive service
8 Our Success! Historical Comparison of Morbidity and Mortality for VPDs Roush, S. W. et al. JAMA 2007;298:
9 Global pediatric efforts are yielding strong successes! Vaccine-preventable diseases responsible for nearly 20% of the 8.8 million deaths/year among children <5 years In 1974, <5% of children were immunized in their first year against 6 targeted diseases WHO launched the Expanded Programme on Immunization (EPI) in 1974 to develop and expand immunization programs around the world By 2005, 80% of children immunized in their first year against 6 targeted diseases EPI efforts prevent an estimated 3 million deaths/year
10 Common denominators we are in this together, at least for children Our current success in immunizing our children is predicated on successful collaborative immunization programs to develop, deliver, administer, and evaluate the vaccines. Vaccines do not give themselves Medical necessity drives vaccine development Public health and clinical recommendations emphasize importance of protection against disease Private/public commitment ensures vaccines are delivered to providers Providers are committed to protecting their pediatric patients Public and private sector payment systems pay adequately for provision of vaccines.
11 Vaccination Programs Are Not Static Collaboration dictates our continued success Disease agents evolve, epidemiology changes Immunization programs must also evolve to keep pace Boosters; new vaccines; new delivery systems New effectiveness and safety data New payment models Infrastructure remains precarious due to erosion of resources for federal, state, and local public health Reactive as opposed to proactive Shift resources as necessary to manage situation
12 But What about Adults? Adult coverage rates are poor No significant infrastructure in place and lack of programmatic support Significant mortality and morbidity 50,000 adults die annually from pneumococcal disease, influenza, hepatitis B in the US. Hundreds of thousands more are hospitalized. Significant cost to the healthcare system ~$15 billion annually in the US based on zoster, pneumococcal disease, influenza, and pertussis
13 Vaccination Coverage for Target Groups by Vaccine, Age, and High-risk Status* Percentage (%) Influenza, HPV in women, Age-based 2012 High Risk 2012 Age-based and older Tdap, Hepatitis B, 19-59, diabetes Pneumococcal (ppv23 or PCV13) *Data source: 2012 National Health Interview Survey. CDC. Adult Vaccination Coverage United States, MMWR 2014; 63(05);
14 Vaccines recommended for older adults Vaccine Coverage % Influenza (65+) ( )** 66.2% (CI ) Pneumococcal (ppv23) (65+)* 59.9% (CI ( ) Zoster (60+)* 20.1% (CI ) *Data source: 2012 National Health Interview Survey ** CDC. FluVaxView. Available at:
15 Burden of Adult Vaccine-preventable Disease Among U.S. Adults Invasive pneumococcal disease (IPD) 1 39,750 total cases and 4,000 total deaths in % of IPD and nearly all IPD deaths among adults Influenza 2 3,000 to 49,000 total related deaths per year ~90% among adults 65 years and older Pertussis 3 ~24,231 total reported cases 2013 ~5,000 among adults Hepatitis B 4 2,890 acute cases reported ,800 estimated Zoster 5 about 1 million cases of zoster annually U.S. 1. CDC. Active Bacterial Core Surveillance. findin gs/survreports/spneu10.pdf. 2. CDC. Estimates of deaths associated with seasonal influenza United States, MMWR. 2010;59(33): CDC. Provisional 2013 Reports of Notifiable Diseases. Available at: mwrhtml/mm6252md.htm?s_cid=mm62 52md_w. 4. CDC. Viral Hepatitis Surveillance United States, National Center for HIV/AIDS, Viral Hepatitis, STD& TB Prevention/Division of Viral Hepatitis. 5. CDC. Prevention of Herpes Zoster. MMWR (RR 5): 1 30.
16 2010 US Census Cost Burden of 4 Adult Vaccine Preventable Diseases to the U.S. Disease Age Group Est. Cases Est. Direct Cost Est. Indirect Cost Est. Total Cost Est. Total Cost (per case) (per case) (per case) (all cases) Influenza 18 14,800,993 a 140 b 377 b 517 $7,652,113,319 S. Pneumoniae ,207 c $4,563,871,132 Bacteremia 50 29,628 c 23,568 d 1,297 d 24,865 $736,696,394 Meningitis 50 1,883 c 29,995 d 1,390 d 31,385 $59,095,033 NPP (inpatient) ,314 c 15,569 d 1,014 d 16,584 $3,438,040,889 NPP (outpatient) ,382 c 549 d 481 d 1,030 $330,038,816 Herpes Zoster ,019 e 1,034 f 2,636 f 3,670 $2,477,318,929 Pertussis ,833 g 395 h 542 h 937 $386,824,301 Total 17,007,258 $15,080,127,681 NPP is non-bacteremic pneumococcal pneumonia caused by S. pneumoniae. 'NPP inpatient' refers to cases of NPP that require hospitalization where as 'NPP outpatient' refers to cases of NPP that do not require hospitalization. All costs were adjusted to 2010 U.S. dollars. McLaughlin, JM., Tan, L., et al JOPP. Manuscript submitted.
17 And adult vaccination commitment and policies vary tremendously across countries* Varying policies recommending: vaccination for adults funding mechanisms for adult vaccine administration, and routine adult vaccination coverage assessment Many countries with advanced economies lack any form of adult immunization policies Newer vaccines are less likely than older ones to be recommended for adults Stable funding, standard recommendations, and routine vaccine coverage assessment are essential components for an adult immunization strategy *Wu, L. et al Available at:
18 Ramifications exist when we fail to vaccinate adults Beyond the impact to the health of the public, our ineffectiveness in immunizing adults: Creates disincentive for manufacturers to enter the market Leaves chronically ill vulnerable Failure to include immunizations as part of adult preventive care for those chronically ill Creates disparities in access to care Absence of commitment exacerbates existing barriers to immunization for those in the lower socioeconomic strata and for the racial and ethnic minorities
19 Disparities are widespread Vaccination Group % Vaccinated Whites Disparity, Blacks Disparity, Hispanics Disparity, Asians Pneumo., HR yrs Pneumo., 65 yrs Tetanus, yrs Tetanus, yrs Tetanus, 65 yrs Tdap, 19 yrs Tdap, yrs Tdap, 65 yrs HepA, yrs HepB, yrs Herpes Zoster, 60 yrs HPV, Females yrs Tdap, HCP 19 yrs HepB, HCP 19 yrs
20 Other Ramifications Exist By failing to prepare, we are preparing to fail - Benjamin Franklin Leaves us vulnerable during times of crisis when the ability to reach 250 million adults with vaccines/medications is crucial Pandemic influenza Our failure to successfully immunize adults in healthy times predicts our failure to immunize them in times of crisis
21 Why is it so hard to vaccinate adults?
22 Barriers to Adult Immunization Competing social and economic demands among adults Competing demands for providers time and vaccines often not integrated into adult medical care practice Adult vaccine schedule is complex Especially for certain occupational and medical target groups Fewer public health resources for adult immunization Pediatric purchases on federal contracts in Dec 2010-Dec 2011: $3,535 billion Adult vaccine purchases: $44 million Limited patient awareness and demand for adult vaccinations except perhaps for influenza vaccine
23 Are any of the following vaccines recommended for you as an adult? Yes (%) No (%) Don t Know (%) Influenza Hepatitis A Hepatitis B Pneumococcal Tdap FallStyles (September-October, 2012). Sheedy.pdf
24 Factors Associated with Low Vaccination Among Adults Patient factors May not have regular health care provider or only see specialists Inconvenient access, competing social and economic demands Many underinsured adults years of age Provider factors Many other health issues compete with preventive services Lack of provider recommendation Lack of effective reminders to offer vaccinations Concern over adequate payment System factors Fewer requirements for vaccination (e.g. by employers) State regulations differ on who can vaccinate and types of vaccine allowed (e.g. pharmacists, visiting nurse associations) Complex adult vaccine schedule
25 Adults - we all can be in it together! 1. Drive demand by improving valuation in both patients and providers! (eg, via education and outreach) 2. Improve access to all adult vaccines by: a) Ensuring supply and delivery by improving infrastructure; b) Initiating/improving surveillance for adult vaccine preventable diseases and vaccine coverage; c) Creating collaborative provider relationships and public-private partnerships to facilitate/promote adult immunization i. Quality Measurement d) Ensuring vaccinations are documented 3. Ensure adequate payment a) Adult immunization should not be a money-losing proposition for providers b) Patients should not have to shoulder large costs to get vaccinated
26 Adults - we all can be in it together! All three steps must be advanced simultaneously. Progress in all areas necessary for success. Leadership (national, provincial, & providerled ) to solicit, initiate, and coordinate solutions Work in each problem area should be coordinated with all other stakeholders in adult immunization and they must be given an opportunity to contribute.
27 Unifying the message bringing us together Leadership to solicit, initiate, and coordinate solutions In the US: National Vaccine Advisory Committee (NVAC) Adult Immunization White Paper June 2011 NEW Adult IZ Practice Standards September 2013 National Adult and Influenza Immunization Summit is an CDC/IAC/NVPO co-sponsored partnership Five WGs established Annual event but year-round engagement Modeled after success of the National Influenza Vaccine Summit
28 Unifying the message bringing us together Leadership to solicit, initiate, and coordinate solutions
29 NEW Adult Immunization Practice Standards Fundamental Paradigm Shift in Adult IZ Adult immunization standards should be applied to all providers of care to adults, those who do and do not vaccinate New standards recognize the importance of the healthcare provider recommendation for patients to receive needed vaccines Highlights the current low vaccination rates among U.S. adults Reflects the changed environment within which adult vaccines are now given
30 Fundamental Paradigm Shift in Adult IZ ALL providers of health care to adults are to: 1. Routinely assess patient s status for all recommended vaccines; 2. Educate and counsel the patient on the recommended vaccines 3. Strongly recommend needed vaccines; ideally, provide the recommended vaccines at the same visit. Providers who do not stock the recommended vaccine are to refer the patient to a vaccinating provider. Follow up! 4. Document the receipt of the recommended vaccine
31 The New Adult IZ Standards of Practice
32 The New Adult IZ Standards of Practice
33 Advocacy Matters!
34 We are in it together a unified message supporting adult IZ To other providers, of the importance of adult immunization Specialists, in particular, see the most vulnerable patients The new paradigm for adult immunization standards in the U.S. is relevant globally To decision makers, of the importance of providing resources to support adult vaccination To the public on the importance of adult vaccines Providers are the most important influencer of vaccine acceptance by patients
35 Maintaining the Future of Immunizations
36 A perspective on the evolution of the vaccine environment Pre-1980s, the public health years 1980s to 2010, the ROI years 2010 to the near future? A rocky path ahead The challenge to evolve and recognize again, that we are all in this together
37 Evolution of vaccine R & D environment over the years pre-1980, the public health years Vaccines seen as a public health good Vaccine prices were low No significant return on investment to vaccine manufacturers No strong leadership to recommend use of vaccines No commitment to invest in vaccines and vaccination programs to improve prevention Liability to manufacturers real and costly, leading to crisis in the early 1980s Manufacturers beginning to leave vaccine R & D
38 Evolution of vaccine R & D environment over the years 1980s to 2010, the ROI years Vaccines seen as good public health value AND good commercial investments Vaccination programs developed to support use of vaccines Leadership commitment to address unmet medical need by preventing disease via immunization Liability to manufacturers ameliorated with the Vaccine Injury Compensation Program New vaccines introduced into programs were paid at prices that were comparable to therapeutic interventions That allowed Returns on Investment (ROI)
39 Evolution of vaccine R & D environment over the years 1980s to 2010, the ROI years These Changes Helped Stimulate New Manufacturers to enter a Growing Market Over the last 2 decades, more than a dozen new vaccines have been introduced and the number of companies developing products has increased. There was re-investment of profits from new vaccines into improving current vaccines and developing new ones as there was now comparable ROI relative to new biologicals and pharmaceuticals. Large and small companies, as well as investors, are continually assessing these ROI s and making decisions on resource allocation priorities. Graphic courtesy of Biotechnology Industry Organization
40 Evolution of vaccine R & D environment over the years 1980s to 2010, the ROI years A positive ROI assessment leads to a win-win situation We have seen drops in infectious diseases as a result of new vaccines, such as pneumococcal conjugate vaccine, rotavirus vaccine, varicella vaccine, and HPV vaccine, when we can get high coverage And we see new vaccines in the pipeline, and new delivery technologies, when the ROI assessment shows promise
41 Evolution of vaccine R & D environment over the years 1980s to 2010, the ROI years Targets for vaccine development include traditional viruses and bacteria, and also noncommunicable diseases. Vaccines may become a key part of anti-microbial stewardship programs. Over the next decade, we may see: New Vaccines for Global Health Malaria Dengue Ebola Tuberculosis Chikungunya New Adult or Pediatric Vaccines Universal influenza Meningococcal A,C, Y, W-135 Meningococcal B CMV RSV Streptococcus vaccines New Healthcare-acquired Infection Vaccines Clostridium difficile Staphylococcus aureus Tuberculosis Pseudomonas aeruginosa Candida BUT Norovirus New combinations of existing pediatric vaccines Graphic courtesy of Biotechnology Industry Organization
42 Evolution of vaccination paradigms over the years Now and Beyond Challenges to the ROI years are showing up New vaccine targets are more difficult the easy ones are all done Clinical trials are more complicated now It is not always possible to do an efficacy trial It s very difficult to detect rare events
43 Evolution of vaccination paradigms over the years Now and Beyond Challenges to the ROI years are showing up Renewed focus on the price of vaccines, as opposed to the value but costs HAVE to go up, and hence prices Constant quality control and FDA-required upgrades of facilities Constant requirement to assess and improve current vaccines New clinical development programs Large clinical trial sizes Post-marketing requirements for safety
44 Vaccines Present a Unique Need for Continuous Investment Increasing Costs R&D Introduction Facility Maintenance New Indications Technology Developments New Vaccine R&D Product Timeline Graphic courtesy of Biotechnology Industry Organization
45 Evolution of vaccination paradigms over the years Now and Beyond Challenges to the ROI years are showing up Under-developed vaccination programs, eg adults! Remember that ROI is dependent on market size Example: relative success of influenza and Tdap vaccination during pregnancy has stimulated development of new vaccines targeted at maternal immunization, such as GBS and RSV Increased concerns over safety Increased risk management/risk communications issue for providers and patients What s the impact on vaccine acceptance? And hence ROI? Spillover into regulatory? How will new vaccine technology be approved? Detection of rare event difficult
46 Evolution of vaccination paradigms over the years Now and Beyond And will a vaccine get a recommendation?! It is now difficult to predict whether a new vaccine will achieve a use recommendation Focus on medical necessity in past years is now replaced with a focus on cost effectiveness (ACIP has much power in the US due to ACA) Vaccines that clearly qualify for a routine recommendation are mostly done; new vaccines now prevent diseases with low incidence, eg meningococcal disease Cost of R & D is now very high Phase III trials are large and complicated Manufacturing facility needs to be built prior to the recommendation
47 Number of subjects enrolled in pivotal vaccine efficacy clinical trials Trial Number subjects enrolled PCV7 ~38, HPV4 ~18, HPV4 ~19, Rotavirus (pentavalent) ~70, Influenza high dose ~32, PCV13 (CAPiTA) ~85, Dengue ~40, Year trial completed
48 Evolution of vaccination paradigms over the years Now and Beyond Uncertainty over a vaccine use recommendation combined with increasing resource intensity (fiscal and otherwise) of development, has increased the risk associated with vaccine R & D
49 So where does that leave us? Aren t we in this together? Academic institutions may start basic research into new vaccines but partnership with a large manufacturer is needed to scale up production There is a high barrier to entry for new manufacturers They will need partners with competency Joint ventures/partnerships are increasingly important in investment decisions Or their project may be sold to a large multinational, who has to satisfy its investors And there is internal competition for dollars
50 So where does that leave us? Aren t we in this together? Most vaccine companies are publicly traded and ROI is a major driver for strategic investment A medical need is no longer enough to drive investment, there has to be an expected ROI The availability and size of the market for the vaccine, if it is licensed, will determine ROI Decisions to develop a new vaccine are no longer based on just medical and public health need Will national governments recommend the vaccine? Will there be public funding for the vaccine? Is the price controlled? What else is already in the market? Relying on the private market for revenue is insufficient for investment purposes
51 So where does that leave us? And the investment decision WILL compete for resources with other potentially more profitable products, eg. drugs, which may have bigger revenues Ultimately, investment in development in new vaccines and technology will occur where there is a commercial reason to do so.
52 How can we all get together to keep preventing diseases through vaccination? Strengthen regulatory science to allow for innovative clinical trial designs that shorten development timelines and reduce costs without impacting safety and efficacy Proactive engagement on new vaccine technology Need balance on safety and efficacy end points Establish clear transparent recommendation processes and regular dialogue between stakeholders and manufacturers during all phases of development Need dialogue on which vaccines are considered to address unmet medical/public health need How will cost effectiveness come into play?
53 How can we all get together to keep preventing diseases through vaccination? Return on investment needs to be comparable to other therapeutic areas to encourage continued participation in vaccine science, and R & D Improve coverage rates in the adult and pregnancy platforms to drive a market Communicate on the known benefits of vaccination for adults and pregnant women Improve access to vaccines for all All providers must give strong recommendations to all patients
54 We ARE all in this together. For the future to remain positive, there must be increased cooperation and communication between the public and private sector Working together, all stakeholders can succeed In order to work together, the value, and the needs, of all partners have to be understood, recognized, and integrated.
55 Visit IAC/Summit Resources! 25% of our website users are outside North America! Use our publications! Visit our websites! Stay ahead of the game! Subscribe to our updates!
56 Amanda, died at age 4½ yrs from influenza Why do we immunize against influenza? Breanne, died at age 15 mos from influenza complications Lucio, died at age 8 yrs from influenza complications 56 Alana, died at age 5½ yrs from influenza Slide Courtesy of Families Fighting Flu Barry, a veteran fire-fighter, died at age 44 yrs from influenza
57 Thank You!
The State of Adult Immunizations in the United States
The State of Adult Immunizations in the United States Litjen (L.J) Tan, MS, PhD Chief Strategy Officer, Immunization Action Coalition Co-Chair, National Adult and Influenza Immunization Summit Adult Immunization
More informationThank you for coming to our Houston Workshop THIS INITIATIVE IS BEING SUPPORTED BY A SPONSORSHIP FROM PFIZER
Thank you for coming to our Houston Workshop THIS INITIATIVE IS BEING SUPPORTED BY A SPONSORSHIP FROM PFIZER Session 1 THIS INITIATIVE IS BEING SUPPORTED BY A SPONSORSHIP FROM PFIZER Disclosure The Immunization
More informationThe State of Adult Immunizations in the United States
The State of Adult Immunizations in the United States Litjen (L.J) Tan, MS, PhD Chief Strategy Officer, Immunization Action Coalition Co-Chair, National Adult and Influenza Immunization Summit Adult Immunization
More informationSession 1 THIS INITIATIVE IS BEING SUPPORTED BY A SPONSORSHIP FROM PFIZER
Session 1 THIS INITIATIVE IS BEING SUPPORTED BY A SPONSORSHIP FROM PFIZER Disclosure The Immunization Action Coalition has been responsible for all aspects of content development for the enclosed presentation
More informationL.J Tan, MS, PhD Immunization Action Coalition Chief Strategy Officer THIS INITIATIVE IS BEING SUPPORTED BY A SPONSORSHIP FROM PFIZER
L.J Tan, MS, PhD Immunization Action Coalition Chief Strategy Officer THIS INITIATIVE IS BEING SUPPORTED BY A SPONSORSHIP FROM PFIZER Disclosure The Immunization Action Coalition has been responsible for
More informationImmunization Across the Lifespan: Vaccinating Adults in the United States
Immunization Across the Lifespan: Vaccinating Adults in the United States Litjen (L.J) Tan, MS, PhD Chief Strategy Officer, Immunization Action Coalition Co-Chair, National Adult and Influenza Immunization
More informationHow are Adult Immunizations paid for in the United States?
How are Adult Immunizations paid for in the United States? Litjen (L.J) Tan, MS, PhD Chief Strategy Officer, Immunization Action Coalition Co-Chair, National Adult and Influenza Immunization Summit February
More informationOutline. Why Adult Immunization Matters. Recommended Adult Vaccines: Age Based. Why Do We Vaccinate? Footnotes. Risk Based
Why Adult Immunization Matters Outline CDC Recommended Adult Vaccines Burden of U.S. adult vaccine preventable disease Vaccine effectiveness in adults Adult immunization coverage rates Ramifications of
More informationVaccine Innovation and Adult Immunization Landscape
Vaccine Innovation and Adult Immunization Landscape National Adult and Influenza Immunization Summit, May 12-14, 2015 Phyllis Arthur Senior Director Vaccines, Immunotherapeutics & Diagnostics Policy parthur@bio.org
More informationAddressing the morbidity, mortality, and cost associated with adult vaccine preventable diseases
Addressing the morbidity, mortality, and cost associated with adult vaccine preventable diseases Litjen (L.J) Tan, MS, PhD Chief Strategy Officer, Immunization Action Coalition Co-Chair, National Adult
More informationSession 1 THIS INITIATIVE IS BEING SUPPORTED BY A SPONSORSHIP FROM PFIZER
Session 1 THIS INITIATIVE IS BEING SUPPORTED BY A SPONSORSHIP FROM PFIZER Disclosure The Immunization Action Coalition has been responsible for all aspects of content development for the enclosed presentation
More informationNational Vaccine Plan: From Strategy to Implementation
National Vaccine Plan: From Strategy to Implementation July 26, 2011 Sarah Landry Senior Advisor, National Vaccine Program Office Office of the Assistant Secretary for Health Department of Health and Human
More informationPresenter Disclosure Information
Disclosure The Immunization Action Coalition has been responsible for all aspects of content development for the enclosed presentation and all other assets supporting the Take a Stand program. Any questions
More informationStanding Orders and Adult Immunizations: A Foundation for Improving Coverage Rates
Standing Orders and Adult Immunizations: A Foundation for Improving Coverage Rates Litjen (L.J) Tan, MS, PhD Chief Strategy Officer, Immunization Action Coalition Co-Chair, United States Adult and Influenza
More informationThe State of Adult Immunizations in the United States
The State of Adult Immunizations in the United States Litjen (L.J) Tan, MS, PhD Chief Strategy Officer, Immunization Action Coalition Co-Chair, National Adult and Influenza Immunization Summit June 13
More informationMaking Progress Towards Improving Adult Immunizations
Making Progress Towards Improving Adult Immunizations May 10, Carolyn B. Bridges, MD Immunization Services Division National Center for Immunization and Respiratory Diseases Centers for Disease Control
More informationImmunization Program Managers Meeting 2010
Immunization Program Managers Meeting 2010 Stewards in a Time of Change Anne Schuchat, MD RADM, US Public Health Service Assistant Surgeon General Director, National Center for Immunization and Respiratory
More informationVaccine Finance. Overview of stakeholder input and NVAC working group draft white paper. Walt Orenstein, MD
Vaccine Finance Overview of stakeholder input and NVAC working group draft white paper Walt Orenstein, MD Consultant to the National Vaccine Program Office July 24, 2008 Number of Vaccines in the Routine
More informationOverall presentation of IVR Strategy
Annex 3 Overall presentation of IVR Strategy Presentation to the IVR Advisory committee (IVAC) April 2007 Outline Why does WHO invest in Research & Development? What is the Initiative for Vaccine Research
More informationJanuary 17, Re: Secretary s Advisory Committee on National Health Promotion and Disease Prevention Objectives for Healthy People 2030
January 17, 2019 Don Wright, MD, MPH, FAAFP Deputy Assistant Secretary for Health Office of Disease Prevention and Health Promotion Department of Health and Human Services Tower Building 1101 Wootton Parkway,
More informationVaccinology Overview. Complexity of the Vaccine Approval Process Including Lessons Learned
Vaccinology Overview Complexity of the Vaccine Approval Process Including Lessons Learned Larry K. Pickering, MD, FAAP, FIDSA, FPIDS August 18, 2018 Faculty Disclosure Information In the past 12 months,
More informationManaging cost considerations and access to technology for cost effective vaccine manufacture in developing countries.
Managing cost considerations and access to technology for cost effective vaccine manufacture in developing countries. Amol R. Dindokar Serum Institute of India ltd. Overview Disease Control Priorities
More informationThe story of modern vaccines begins in 1749, when Dr. Edward Jenner observed that milkmaids exposed to cowpox later subsequently not contract
1 The story of modern vaccines begins in 1749, when Dr. Edward Jenner observed that milkmaids exposed to cowpox later subsequently not contract smallpox. Dr. Jenner used fluids from a cow s blisters to
More informationVACCINES TRIUMPHS AND TRIBULATIONS. William Schaffner, MD Chairman, Department of Preventive Medicine Vanderbilt University School of Medicine
VACCINES TRIUMPHS AND TRIBULATIONS William Schaffner, MD Chairman, Department of Preventive Medicine Vanderbilt University School of Medicine Never in the history of human progress has a better and cheaper
More informationImplementing Standing Orders Protocols Making a Difference in Immunization Rates
Implementing Standing Orders Protocols Making a Difference in Immunization Rates Litjen (L.J.) Tan, MS, PhD Chief Strategy Officer Immunization Action Coalition Co-Chair National Adult and Influenza Immunization
More informationVaccine Innovation: Challenges and Opportunities to Protect Health. Julie Louise Gerberding, M.D., M.P.H President, Merck Vaccines
Vaccine Innovation: Challenges and Opportunities to Protect Health Julie Louise Gerberding, M.D., M.P.H President, Merck Vaccines Protecting Health with Vaccines HEALTH IMPROVEMENT Population Impact Guidelines
More informationOn behalf of the Infectious Diseases Society of America (IDSA), I am pleased to provide
Transmitted by Jonathan Nurse, Director of Government Relations, IDSA The Infectious Diseases Society of America s (IDSA) Fiscal Year 2015 Funding Statement Submitted to the House Appropriations Subcommittee
More informationThe Affordable Care Act (ACA) and Immunizations Discussing the Challenges
The Affordable Care Act (ACA) and Immunizations Discussing the Challenges Litjen (L.J) Tan, MS, PhD Chief Strategy Officer, Immunization Action Coalition Co-Chair, National Adult and Influenza Immunization
More informationIndiana Immunization Task Force Progress Report
Indiana Immunization Task Force Progress Report Report Published December 2009 Progress Report Published May 31, 2012 2344 Broadway Street, Indianapolis, IN 46205 Tel: 317-628-7116 Email: director@vaccinateindiana.org
More information'Contagious Comments' Department of Epidemiology
'Contagious Comments' Department of Epidemiology Vaccine-Preventable Diseases in Colorado s Children, 27 Sean O Leary MD, Elaine Lowery JD MSPH, Carl Armon MSPH, James Todd MD Vaccines have been highly
More informationVaccine-Preventable Diseases in Colorado s Children 2009 Sean O Leary MD, Carl Armon PhD, Joni Reynolds, RNC, MSN, James Todd MD
State of the Health of Colorado s Children Vaccine-Preventable Diseases in Colorado s Children 29 Sean O Leary MD, Carl Armon PhD, Joni Reynolds, RNC, MSN, James Todd MD Vaccines have been highly effective
More informationGAVI ALLIANCE: UPDATE AND FUTURE DIRECTIONS FOR GLOBAL VACCINES AND IMMUNISATIONS
GAVI ALLIANCE: UPDATE AND FUTURE DIRECTIONS FOR GLOBAL VACCINES AND IMMUNISATIONS Ranjana Kumar International Rotavirus Symposium Istanbul, 3 4 June 2008 The GAVI Alliance Public-private partnership bringing
More informationWHY WE RE HERE. Melinda Wharton, MD, MPH Director, Immunization Services Division. National Center for Immunization & Respiratory Diseases
National Center for Immunization & Respiratory Diseases WHY WE RE HERE Melinda Wharton, MD, MPH Director, Immunization Services Division AIM Leadership Conference February 8, 2017 Vaccines save lives.
More informationAdult Immunizations & the Workplace
Adult Immunizations & the Workplace Samuel B. Graitcer, MD Office of Associate Director for Adult Immunizations Immunization Services Division National Center for Immunization & Respiratory Diseases Immunization
More informationSeptember 10, To Whom It May Concern:
September 10, 2018 Centers for Medicare & Medicaid Services Department of Health and Human Services Attention: CMS-1691-P P.O. Box 8010, Baltimore, MD 21244-8010 RE: CMS-1691-P Medicare Program; End-Stage
More informationDeaths/yr Efficacy Use Prev Deaths/yr. Influenza 36,000 70% 60% 18,000. Pneumonia 40,000 60% 40% 20,000 HBV 6,000 90% 30% 4,000
Tetanus, Diptheria, Pertussis,! Measles, Mumps, Rubella, Varicella, HPV, Polio Meningococcus, Pneumococcus,! Influenza, Hepatitis B, Hepatitis A,! H influenza, Rabies, Typhoid,! Yellow Fever, Japanese
More informationEconomics of Vaccine Development A Vaccine Manufacturer s Perspective
Economics of Vaccine Development A Vaccine Manufacturer s Perspective Gerald Voss The Value of Vaccines 2 29 diseases are currently preventable by vaccination Global public health Cervical cancer 1 Diphtheria
More informationGlobal Health Policy: Vaccines
Global Health Policy: Vaccines Edwin J. Asturias Senior Investigator Colorado School of Public Health Department of Pediatrics Children s Hospital Colorado UNIVERSITY OF COLORADO COLORADO STATE UNIVERSITY
More informationAdult Immuniza-on Update
Adult Immuniza-on Update Maggie Zettle, PharmD Lieutenant, United States Public Health Service Management Analyst, National Vaccine Program OfBice U.S. Department of Health and Human Services Overview
More informationVACCINES FOR ALASKANS: ALASKA VACCINE ASSESSMENT PROGRAM
VACCINES FOR ALASKANS: ALASKA VACCINE ASSESSMENT PROGRAM MCH-Immunization Conference September 24, 2014 Joe McLaughlin MD, MPH Rosalyn Singleton MD Gerri Yett RN, MSN, CHES Alaska Section of Epidemiology
More informationOpportunities for Developing Measures for Adult Vaccines
Opportunities for Developing s for Adult Vaccines May 15, 2012 National Adult Immunization Summit Tilithia McBride Avalere Health LLC Why s? VA Program Demonstrates Success of ment to Improve Vaccination
More informationMandates and More. Julie Morita, M.D. Deputy Commissioner Chicago Department of Public Health. Chicago Department of Public Health
Mandates and More Julie Morita, M.D. Deputy Chicago Department of Public Health Why are vaccines required for school entry? School Vaccine Requirements Small pox vaccine required in Massachusetts 1855
More informationCalifornia Department of Public Health California Department of Public Health California Department of Public Health
2012 CIC Education Hour: January 24, 2012 Navigating Adolescent Vaccinations through Private and Safety Net Providers Contact Information Claudia Aguiluz, VFC Program Coordinator Claudia.aguiluz@cdph.ca.gov
More informationAdult Immunizations Carolyn B. Bridges, MD
Adult Immunizations Carolyn B. Bridges, MD Immunization Services Division National Center for Immunization and Respiratory Diseases CDC November 2012 National Center for Immunization & Respiratory Diseases
More informationCombination of the Pediatric and Adolescent Schedules
Immunization Update 2013 William Buoni, MD Assistant Professor-Clinical Department of Family Medicine The Ohio State University Wexner Medical Center Outline Vaccine update Combined child/adolescent immunization
More informationWilliam Buoni, MD Assistant Professor-Clinical Department t of Family Medicine The Ohio State University Wexner Medical Center
Immunization Update 2013 William Buoni, MD Assistant Professor-Clinical Department t of Family Medicine i The Ohio State University Wexner Medical Center Outline Vaccine update Combined child/adolescent
More informationHEALTHY CANADIANS AND SUSTAINED ECONOMIC RECOVERY: PREDICTABLE VACCINE FUNDING IN CANADA
HEALTHY CANADIANS AND SUSTAINED ECONOMIC RECOVERY: PREDICTABLE VACCINE FUNDING IN CANADA HOUSE OF COMMONS STANDING COMMITTEE ON FINANCE 2012 PRE-BUDGET CONSULTATIONS EXECUTIVE SUMMARY Merck Canada is pleased
More informationHealthy People 2020 objectives were released in 2010, with a 10-year horizon to achieve the goals by 2020.
Appendix 1: Healthy People 2020 Immunization-related Objectives Healthy People provides science-based, 10-year national objectives for improving the health of all Americans. For three decades, Healthy
More informationAdult Immunization Rates
Adult Immunization Rates California Immunization Coalition Summit May 5, 2014 Eileen Yamada, MD, MPH California Department of Public Health Immunization Branch Adult Immunization Rates California Data
More informationUpdate on Vaccine Recommendations. Objectives. Childhood Immunization Schedule At the Turn of the Century. New Horizons in Pediatrics April 30, 2017
Centers for for Disease Disease Control Control and and Prevention Prevention National Center for Immunization and Respiratory Diseases Update on Vaccine Recommendations New Horizons in Pediatrics April
More informationReport to the Board 6-7 June 2018
6-7 June 2018 SUBJECT: VACCINE INVESTMENT STRATEGY: SHORT LIST Agenda item: 07 Category: For Decision Section A: Introduction This report presents outcomes of the Phase II analyses for the Vaccine Investment
More informationMaternal Immunization: Unique considerations of public health value of vaccines given to pregnant women
Maternal Immunization: Unique considerations of public health value of vaccines given to pregnant women Estimating the full public health value of vaccines Kathleen M. Neuzil, MD, MPH Professor of Medicine
More informationIOM Committee on Assessment of Studies of Health Outcomes Related to the Recommended Childhood Immunization Schedule
IOM Committee on Assessment of Studies of Health Outcomes Related to the Recommended Childhood Immunization Schedule Bruce Gellin, MD, MPH Director, National Vaccine Program Office Deputy Assistant Secretary
More informationSanofi Pasteur: A partner in eradicating vaccine preventable diseases and improving access to vaccines
Sanofi Pasteur: A partner in eradicating vaccine preventable diseases and improving access to vaccines 1 Vaccines: the single most effective medical intervention 2 Vaccines save lives Millions of cases
More informationSession 2 THIS INITIATIVE IS BEING SUPPORTED BY A SPONSORSHIP FROM PFIZER
Session 2 THIS INITIATIVE IS BEING SUPPORTED BY A SPONSORSHIP FROM PFIZER Disclosure The Immunization Action Coalition has been responsible for all aspects of content development for the enclosed presentation
More informationRe: Trust for America s Health Comments on Biennial Implementation Plan for the National Health Security Strategy
Dr. Nicole Lurie, MD, MSPH Assistant Secretary for Preparedness & Response Department of Health and Human Services Washington, DC 20201 Re: Trust for America s Health Comments on Biennial Implementation
More informationOverview. Vaccine innovation With people, for people: The (A) citizens' view. Vaccine impact in perspective. Vaccine research in perspective
Overview Vaccine innovation With people, for people: The (A) citizens' view Disclaimer about the citizen Ending AIDS? A history lesson A way forward hopefully Mitchell Warren Executive Director, AVAC 12
More informationIncreasing Adult Immunization Rates in the US Through Data and Quality: A Roadmap
Increasing Adult Immunization Rates in the US Through Data and Quality: A Roadmap Avalere Health An Inovalon Company November 16, 2017 In Partnership with GSK Agenda 1 2 3 4 5 Welcome & Introductions Overview:
More informationU.S. Adult Immunization Program
National Center for Immunization & Respiratory Diseases U.S. Adult Immunization Program Carolyn B Bridges, MD Immunization Services Division NCIRD, CDC March 6, 2017 Outline Overview of US adult vaccine
More informationMarch 1, RE: 2020 Medicare Advantage and Part D Advance Notice and Draft Call Letter (CMS )
March 1, 2019 Seema Verma Administrator Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, MD 21244 RE: 2020 Medicare Advantage and Part D Advance Notice and Draft Call Letter
More informationWhy GAVI Needs to Do More To Ensure Lower Vaccine Prices And How It Could Be Done
Why GAVI Needs to Do More To Ensure Lower Vaccine Prices And How It Could Be Done Vaccines are widely considered a highly cost-effective public health intervention. Médecins Sans Frontières (MSF) is actively
More informationPlatforms. Adolescent Immunization Update and the 16 Year Old Platform. Advisory Committee on Immunization Practices (ACIP)
Adolescent Immunization Update and the 16 Year Old Platform William Atkinson, MD, MPH Associate Director for Immunization Education Immunization Action Coalition Advisory Committee on Immunization Practices
More informationSession 2 THIS INITIATIVE IS BEING SUPPORTED BY A SPONSORSHIP FROM PFIZER
Session 2 THIS INITIATIVE IS BEING SUPPORTED BY A SPONSORSHIP FROM PFIZER Disclosure The Immunization Action Coalition has been responsible for all aspects of content development for the enclosed presentation
More informationWHO WE ARE WHAT WE DO
WHO WE ARE In Virginia, the major community partners engaged in health reform -- health care providers, health systems, health plans, pharmaceutical manufacturers and laboratory companies, employers, consumers,
More informationGAVI S VACCINE INVESTMENT STRATEGY
GAVI S VACCINE INVESTMENT STRATEGY Judith Kallenberg, Head of Policy PDVAC 22 June 2017, Geneva Reach every child www.gavi.org Gavi finances vaccines and immunisation through three routes ($9 Billion in
More informationWHO HHS Workshop on Business Modeling for Sustainable Influenza Vaccine Manufacturing
WHO HHS Workshop on Business Modeling for Sustainable Influenza Vaccine Manufacturing Washington, DC January 14th 16th, 2013 Session 4: Attracting Investments and Generating Revenue Theory, Practice and
More informationTargeted Diseases and Immunization. Strategic plan
Targeted Diseases and Immunization Strategic plan 2008-2013 Communicable Diseases Unit WHO Regional Office for Europe Mission To provide technical support to WHO European Region Member States to ensure
More informationThe English immunization programme
The English immunization programme Mary Ramsay Head of Immunisation Public Health England National Health Service Constitution (2009) You have the right to receive the vaccinations that the Joint Committee
More informationOVERVIEW OF THE NATIONAL CHILDHOOD IMMUNISATION PROGRAMME IN SINGAPORE
OVERVIEW OF THE NATIONAL CHILDHOOD IMMUNISATION PROGRAMME IN SINGAPORE Dr Tiong Wei Wei, MD, MPH Senior Assistant Director Policy and Control Branch, Communicable Diseases Division Ministry of Health 9
More informationWorld Health Organization. A Sustainable Health Sector
World Health Organization A Sustainable Health Sector Response to HIV Global Health Sector Strategy for HIV/AIDS 2011-2015 (DRAFT OUTLINE FOR CONSULTATION) Version 2.1 15 July 2010 15 July 2010 1 GLOBAL
More informationThe National Vaccine Advisory Committee: Reducing Patient and Provider Barriers to Maternal Immunizations
The National Vaccine Advisory Committee: Reducing Patient and Provider Barriers to Maternal Immunizations Executive Summary Maternal immunization provides important health benefits for pregnant women and
More informationImmunization Update Texas Immunization Conference
Immunization Update 2017 Texas Immunization Conference Agenda NIS Child and Teen Coverage Levels Adult Program Updates TVFC Influenza Updates TVFC Program Updates 2 1 CDC National Immunization Survey Childhood
More informationGlobal Health Policy: Vaccines
Global Health Policy: Vaccines Edwin J. Asturias Senior Investigator Colorado School of Public Health Department of Pediatrics Children s Hospital Colorado UNIVERSITY OF COLORADO COLORADO STATE UNIVERSITY
More informationFISCAL YEAR 2020 APPROPRIATIONS REQUESTS (updated ) USAID Global Health Programs (GHP) and State Department
FISCAL YEAR 2020 APPROPRIATIONS REQUESTS (updated 2.13.19) Contact: Brian Massa, Senior Manager for Global Health Advocacy, Shot@Life (bmassa@unfoundation.org) USAID Global Health Programs (GHP) and State
More informationCenters for Disease Control and Prevention (CDC) Coalition C/o American Public Health Association 800 I Street NW Washington, DC,
Centers for Disease Control and Prevention (CDC) Coalition C/o American Public Health Association 800 I Street NW Washington, DC, 20001 202-777-2514 Donald Hoppert, Director of Government Relations, American
More information50th DIRECTING COUNCIL 62nd SESSION OF THE REGIONAL COMMITTEE
PAN AMERICAN HEALTH ORGANIZATION WORLD HEALTH ORGANIZATION 50th DIRECTING COUNCIL 62nd SESSION OF THE REGIONAL COMMITTEE Washington, D.C., USA, 27 September -1 October 2010 CD50/DIV/9 ORIGINAL: SPANISH
More information2016/17 Vaccination and Immunisation list of additional services and enhanced services
2016/17 Vaccination and Immunisation list of additional services and enhanced services 2016/17 Vaccination and Immunisation list of additional services and enhanced services Version number: 1 First published:
More information3 rd Immunization Congress: Financing Across the Lifespan Report Out
3 rd Immunization Congress: Financing Across the Lifespan Report Out AAP American Academy of Pediatrics GSA Gerontological Society of America NFID National Foundation for Infectious Disease NVPO National
More informationIntroduction and overview of the program; new vaccine pipeline and prioritization process
Immunization for the Modern Family: Western Canada Immunization Forum 2011 Introduction and overview of the program; new vaccine pipeline and prioritization process Monika Naus, MD, MHSc, FRCPC, FACPM
More informationStanding Orders Protocols Increase Adult Immunizations
Standing Orders Protocols Increase Adult Immunizations William Atkinson, MD, MPH Associate Director for Immunization Education Immunization Action Coalition Saint Paul, Minnesota Immunization Action Coalition
More informationImproving HPV Vaccine Coverage Why We Must and How We Can Do Better
National Center for Immunization & Respiratory Diseases Improving HPV Vaccine Coverage Why We Must and How We Can Do Better Melinda Wharton, MD, MPH Director, Immunization Services Division Illinois State
More information1. The World Bank-GAVI Partnership and the Purpose of the Review
1. The World Bank-GAVI Partnership and the Purpose of the Review 1.1 The new World Bank Group strategy makes a strong case for an expanded World Bank Group role in global and regional dialogue and collective
More informationHow does Gavi make vaccine investment decisions?
How does Gavi make vaccine investment decisions? Judith Kallenberg Global Vaccine and Immunization Research Forum Johannesburg, South-Africa, 16 March 2016 www.gavi.org Vaccine Investment Strategy (VIS)
More informationFifth report of Committee A
SIXTY-EIGHTH WORLD HEALTH ASSEMBLY (Draft) A68/73 26 May 2015 Fifth report of Committee A (Draft) Committee A held its twelfth and thirteenth meetings on 25 May 2015 under the chairmanship of Dr Eduardo
More informationSummary of the National Adult and Influenza Vaccine Summit (NAIIS) May 14-16, L.J Tan Chief Strategy Officer, IAC Co-Chair, NAIIS
Summary of the National Adult and Influenza Vaccine Summit (NAIIS) May 14-16, 2013 L.J Tan Chief Strategy Officer, IAC Co-Chair, NAIIS The United States National Influenza Vaccine Summit is A partnership
More informationImmunization Accomplishments and Challenges, 2017
National Center for Immunization & Respiratory Diseases Immunization Accomplishments and Challenges, 2017 Cindy Weinbaum MD MPH Acting Director, Immunization Services Division Texas Immunization Conference
More informationRoutine Adult Immunization: American College of Preventive Medicine Practice Policy Statement, updated 2002
Routine Adult Immunization: American College of Preventive Medicine Practice Policy Statement, updated 2002 Ann R. Fingar, MD, MPH, and Byron J. Francis, MD, MPH Burden of suffering Vaccines are available
More information21 st Century Vaccine Challenges
21 st Century Vaccine Challenges Presentation by Rosalyn Singleton MD, ANTHC Slides adapted from original powerpoint by: Carrie L. Byington, MD HA and Edna Benning Presidential Professor of Pediatrics
More informationACIP Recommendations for Pneumococcal 13-valent Conjugate and 23-valent Polysaccharide Vaccine Use among Adults
ACIP Recommendations for Pneumococcal 13-valent Conjugate and 23-valent Polysaccharide Vaccine Use among Adults National Center for Immunization & Respiratory Diseases Respiratory Diseases Branch ACIP
More informationGovernment of Bangladesh
Gavi Full Country Evaluations Findings Summary of recommendations Expanded Programme on Immunization Government of Gavi Secretariat With country-level partners, target efforts on low coverage areas and
More informationIntercell and Novartis form world leading strategic partnership to drive vaccines innovation
Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell
More informationHow new vaccines are introduced into programs & why programs differ across Canada
How new vaccines are introduced into programs & why programs differ across Canada Western Canada Immunization Forum January 30, 2018 Monika Naus MD MHSc FRCPC FACPM BC Centre for Disease Control School
More information1. Executive Summary 2. Worldwide Pediatric Vaccines Market and Forecast ( ) 3. Worldwide Pediatric Vaccines Market Share & Forecast (Sector
1. Executive Summary 2. Worldwide Pediatric Vaccines Market and Forecast (2006 ) 3. Worldwide Pediatric Vaccines Market Share & Forecast (Sector wise) (2005 ) 4. Worldwide Pediatric Vaccines Market Share
More informationSupporting State and Local Immunization Programs Brock A. Lamont, MPA Chief, Program Operations Branch Immunization Services Division
Supporting State and Local Immunization Programs Brock A. Lamont, MPA Chief, Program Operations Branch Immunization Services Division Texas Immunization Summit 2014 November 6, 2014 San Antonio, TX I do
More informationI do not have any relevant conflicts of interest to disclose.
Supporting State and Local Immunization Programs Brock A. Lamont, MPA Chief, Program Operations Branch Immunization Services Division I do not have any relevant conflicts of interest to disclose. Texas
More informationBeyond Seasonal Influenza
HHS Adult Immunization Task Force - Disparities Workgroup Beyond Seasonal Influenza adult immunizations(tetanus, varicella, HPV, zoster, MMR, pneumococcal, meningococcal, and hepatitis A+B) A NATION FREE
More informationVaccine Decision-Making
Key Points Vaccine Decision-Making * Decisions on introducing new vaccines have long-term implications for immunization costs as well as logistics systems and service delivery. The choice of vaccine presentation
More informationVACCINE MARKETS OVERVIEW SESSION
VACCINE MARKETS OVERVIEW SESSION Robyn Iqbal Program Officer, Vaccine Delivery Market Dynamics UNICEF SD Manufacturers Meeting Copenhagen October 8, 2014 DRAFT Bill & Melinda Gates Foundation DISCUSSION
More informationTowards the Achievement of GHSA 2024 s Overarching Targets
정보화파트업무계획 [GHSA] Immunization Towards the Achievement of GHSA 2024 s Overarching Targets 2016년추진업무및 2017년업무계획 ( 사업관리 ) 7 th November 2018 Korea Centers for Disease Control and Prevention I. Overview Contents
More informationImmunization Program Resources: Planning and Forecasting Immunization Program Managers Meeting Atlanta, Georgia July 11, 2014
Immunization Program Resources: Planning and Forecasting Immunization Program Managers Meeting Atlanta, Georgia July 11, 2014 Kristin Pope, Associate Director for Policy National Center for Immunization
More information